Subtype
Small Cell Neuroendocrine Carcinoma
CI-CAN-00003964SCNECExplore in graph →
396 active trials6 approved drugs7 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003964SCNECExplore in graph →
Clinical trials
1,165 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (168)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04790955 | Effect of Combination Therapy on SCLC After Initial Treatment Failure | unknown | — | 48 | First Affiliated Hospital of Harbin Medical UniversityOTHER | 0 | Mar 10, 2021 | clinicaltrials |
| NCT04782089 | Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer | unknown | N/A | 20 | Qilu Hospital of Shandong UniversityOTHER | 0 | Mar 4, 2021 | clinicaltrials |
| NCT04543916 | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | withdrawn | Phase 1 / Phase 2 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT04691063 | The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC. | unknown | Phase 3 | 486 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 26, 2021 | clinicaltrials |
| NCT03009682 | Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations(SUKSES-B) | completed | Phase 2 | 15 | Samsung Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT03428607 | Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] | completed | Phase 2 | 26 | Samsung Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT01470248 | Study of Arsenic Trioxide in Small Cell Lung Cancer | completed | Phase 2 | 20 | Emory UniversityOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT04757779 | A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer | unknown | Phase 2 | 40 | First People's Hospital of HangzhouOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT03059667 | Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | completed | Phase 2 | 73 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT04731909 | Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer | unknown | N/A | 80 | Third Military Medical UniversityOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT04490421 | Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. | unknown | Phase 3 | 45 | Fuzhou General HospitalOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT04740021 | Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 46 | Taizhou HoudeAoke Biomedical Co., Ltd.INDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT02171325 | Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment | unknown | Phase 2 | 54 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04500145 | Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer | unknown | Phase 3 | 350 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02337712 | Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer | unknown | Phase 2 | 198 | Sun Yat-sen UniversityOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT03227016 | Study in Patients With SCLC of Veliparib in Combination With Topotecan | unknown | Phase 1 | 30 | Central European Society for Anticancer Drug ResearchOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT04721184 | Impact of Low Muscle Mass in HNC Treated With Immunotherapy(IMMUNONUTRI) | unknown | — | 120 | Institut Català d'OncologiaOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT04696939 | Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients | unknown | Phase 2 | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04683198 | Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC | unknown | Phase 2 | 69 | Chinese Academy of Medical SciencesOTHER | 0 | Dec 24, 2020 | clinicaltrials |
| NCT04684017 | Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer | unknown | Phase 2 | 29 | Shanghai Chest HospitalOTHER | 1 | Dec 24, 2020 | clinicaltrials |
| NCT00466466 | Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients | completed | Phase 1 | 20 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 21, 2020 | clinicaltrials |
| NCT03516084 | A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer | terminated | Phase 3 | 185 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04675697 | Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer | unknown | Phase 2 | 36 | Xiangya Hospital of Central South UniversityOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT04672759 | A Real-world Study of Durvalumab for Lung Cancer in China | unknown | — | 100 | Peking Union Medical College HospitalOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04663438 | Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC | unknown | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Dec 11, 2020 | clinicaltrials |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 483 | United TherapeuticsINDUSTRY | 23 | Dec 9, 2020 | clinicaltrials |
| NCT04659785 | A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） | unknown | Phase 1 / Phase 2 | 53 | Tianjin Medical University Second HospitalOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT03547804 | A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer(MK 01) | completed | Phase 2 | 31 | The First Hospital of Jilin UniversityOTHER | 1 | Dec 1, 2020 | clinicaltrials |
| NCT04647357 | A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer | unknown | Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 30, 2020 | clinicaltrials |
| NCT00765973 | Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors | completed | Phase 1 | 14 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04620837 | Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy | unknown | Phase 2 | 25 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT00415363 | Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy | completed | Phase 2 | 109 | Eli Lilly and CompanyINDUSTRY | 5 | Nov 5, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)(NeoFIND) | terminated | Phase 2 | 19 | Advanced Accelerator ApplicationsINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT03116971 | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) | terminated | Phase 1 | 2 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 13 | Sep 16, 2020 | clinicaltrials |
| NCT01859741 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy(PINNACLE) | terminated | Phase 1 / Phase 2 | 172 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04535739 | PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study | unknown | Phase 3 | 414 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT02499770 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) | completed | Phase 1 / Phase 2 | 122 | G1 Therapeutics, Inc.INDUSTRY | 7 | Aug 21, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT04501029 | A Study of Gimatecan (ST1481) in Small Cell Lung Cancer | unknown | Phase 2 | 70 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Aug 6, 2020 | clinicaltrials |
| NCT03607682 | Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer | terminated | N/A | 2 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 4, 2020 | clinicaltrials |
| NCT03734913 | A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 65 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03026166 | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 42 | AbbVieINDUSTRY | 5 | Jul 17, 2020 | clinicaltrials |
| NCT03389087 | Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 10, 2020 | clinicaltrials |
| NCT03904719 | CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC) | unknown | Phase 2 | 30 | AnewPharmaINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT01450761 | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | completed | Phase 3 | 1,351 | Bristol-Myers SquibbINDUSTRY | 34 | Jul 8, 2020 | clinicaltrials |
| NCT04453930 | A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） | unknown | Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04451460 | Effect of Hyponatremia in Small Cell Lung Cancer | completed | — | 466 | Ankara City Hospital BilkentOTHER | 0 | Jun 30, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Mar 10, 2021source: clinicaltrials